Clareo Health | High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Changhai Hospital
With
The General Hospital of Eastern Theater Command
Shanghai Chest Hospital
Fujian Provincial Hospital
Shanghai Changzheng Hospital
The First Affiliated Hospital of Bengbu Medical University
The First People's Hospital of Changzhou
Second Affiliated Hospital of Wannan Medical College
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed metastatic lung adenocarcinoma
Progression of imaging-confirmed extracranial lesions after first- or second-line treatment with Osimertinib
Previous genetic testing for a definite EGFR-sensitive mutation and imaging-confirmed extracranial lesion progression after first-line treatment with Osimertinib; or previous genetic testing for a definite T790M mutation and imaging-confirmed extracranial lesion progression after second-line treatment with Osimertinib.
Pre-existing clinical benefit after treatment with Osimertinib, including CR, PR, SD (duration \>6 months);
Patients with at least 1 measurable lesion according to the criteria for evaluating the efficacy of solid tumors (RECIST 1.1)
Normal functioning of major organs
Pre-menopausal women of childbearing potential with a negative serum or urine pregnancy test within 7 days prior to the first dose of the drug
Subjects volunteered and signed a written informed consent form.
You may not be if
Previous chemotherapy or immunotherapy
Patients with non-lung adenocarcinoma, including squamous lung cancer or mixed histological types
Progression of imaging-confirmed extracranial lesions after prior Osimertinib treatment with accessible treatment options after genetic testing
Patients with symptomatic brain metastases, meningeal metastases or spinal cord compression
Any unrecovered CTCAE \> grade 1 toxicity reaction following prior Osimertinib treatment at the start of study drug therapy
Other malignant tumors within 5 years or history of other malignant tumours; except effectively controlled basal cell carcinoma of the skin, carcinoma in situ of the uterine cervix, ductal carcinoma in situ of the breast, papillary carcinoma of the thyroid, superficial bladder tumors, etc.
History of interstitial pneumonia with previous diagnosis
Other circumstances that, in the judgement of the investigator, make them unsuitable for inclusion in the study
